Abstract
Despite advances in the treatment of vasculitis, modern therapies fail to induce or maintain remission in a significant proportion of patients. Mycophenolic acid is increasingly used to treat vasculitis syndromes. Here, we consider relevant pharmacokinetic and pharmacodynamic properties of mycophenolate, with emphasis on the impact of renal impairment, and we review the existing evidence for and current trials of mycophenolate in the treatment of primary systemic vasculitides.
MeSH terms
-
Animals
-
Enzyme Inhibitors / pharmacokinetics
-
Enzyme Inhibitors / pharmacology
-
Enzyme Inhibitors / therapeutic use*
-
Humans
-
IMP Dehydrogenase / antagonists & inhibitors*
-
IMP Dehydrogenase / physiology
-
Mycophenolic Acid / analogs & derivatives
-
Mycophenolic Acid / pharmacokinetics
-
Mycophenolic Acid / pharmacology
-
Mycophenolic Acid / therapeutic use*
-
Prodrugs / pharmacokinetics
-
Prodrugs / pharmacology
-
Prodrugs / therapeutic use
-
Randomized Controlled Trials as Topic / methods
-
Signal Transduction / drug effects
-
Signal Transduction / physiology
-
Systemic Vasculitis / drug therapy*
-
Systemic Vasculitis / enzymology*
-
Treatment Outcome
Substances
-
Enzyme Inhibitors
-
Prodrugs
-
IMP Dehydrogenase
-
IMPDH1 protein, human
-
Mycophenolic Acid